In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...